期刊文献+

长期使用活性维生素D安全性的相关性研究 被引量:3

Study of the safety of long-term use of active vitamin D
下载PDF
导出
摘要 目的对连续和间断服用活性维生素D治疗6个月的骨质疏松症者,测24 h尿钙定量比较,了解长期使用活性维生素D的安全性。方法采用美国GE公司生产的Luner Prodigy Advance型骨密度仪测定骨密度确定为骨质疏松者106例。56例患者连续服用活性维生素D6个月为治疗组,50例患者间断服用活性维生素D6个月为对照组。采用美国强生VIPRO 250仪器干化学法测定24 h尿钙定量。采用德国罗氏MODULAR PPISE 900仪器酶速率法测定血液生化指标。结果治疗组与对照组相比,差异无显著性(P>0.05)。结论肝肾功能正常的骨质疏松患者,生理剂量内活性维生素D连续服用6个月,对机体是安全的。 Objective To investigate the safety of long-term use of active vitamin D by detecting 24-hour urinary calcium in patients who received 6-month continuous or intermittent therapy of oral active vitamin D for the treatment of osteoporosis. Methods A total of 106 patients, who were diagnosed with osteoporosis by detecting bone mineral density using Luner Prodigy Advance bone absorptiometry ( GE Co. , USA) , were included in this study. Fifty-six patients in treatment group continuously took active vitamin D for 6 months, while 50 patients in control group intermittently took active vitamin D for 6 months. The quantitative 24-hour urinary calcium was detected using dry chemical method with VIPRO 250 devices (Johnson & Johnson, USA). The blood biochemical parameters were measured using enzyme velocity method with MODULAR PPISE 900 devices (Roche, Germany). Results No significant difference between the 2 groups was observed (P 〉 0.05). Conclusion For the osteoporosis patients with normal liver and renal function, it is safe to administer physiological doses of active vitamin D for 6 months.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2013年第7期707-709,共3页 Chinese Journal of Osteoporosis
关键词 骨质疏松 活性维生素D 尿钙 生理剂量 肝肾功能正常 安全 Osteoporosis Active vitamin D Urinary calcium Physiological dose Normal liver and kidney function Safe
  • 相关文献

参考文献1

二级参考文献18

  • 1Gao L,Tao Y,Zhang L,et al.Vitamin D receptor genetic polymorphisms and tuberculosis:updated systematic review and meta-analysis.Int J Tuberc Lung Dis,2010,14:15-23.
  • 2Kostner K,Denzer N,Muller CS,et al.The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer:a review of the literature.Anticancer Res,2009,29:3511-3536.
  • 3Yu XD,Shen XM,Xue MB,et al.Vitamin D receptor gene polymorphism and bone mineral density in 0-6-year-old Han children.J Bone Miner Metab,2011,29:54-61.
  • 4Matilainen JM,Malinen M,Turunen MM,et al.The number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells.J Biol Chem,2010,285:24174-24183.
  • 5Nakabayashi M,Yamada S,Yoshimoto N,et al.Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs:structural basis for vitamin D receptor antagonism and partial agonism.J Med Chem,2008,51:5320-5329.
  • 6Teichert A,Arnold LA,Otieno S,et al.Quantification of the vitamin D receptor-coregulator interaction.Biochemistry,2009,48:1454-1461.
  • 7Oda Y,Sihlbom C,Chalkley RJ,et al.Two distinct coactivators,DRIP/mediator and SRC/p160,are differentially involved in vitamin D receptor transactivation during keratinocyte differentiation.Mol Endocrinol,2003,17:2329-2339.
  • 8Zhang X,Dowd DR,Moore MC,et al.Meningioma 1 is required for appropriate osteoblast proliferation,motility,differentiation,and function.J Biol Chem,2009,284:18174-18183.
  • 9Kim JY,Son YL,Lee YC.Involvement of SMRT corepressor in transcriptional repression by the vitamin D receptor.Mol Endocrinol,2009,23:251-264.
  • 10Kim JY,Son YL,Lee YC.A role of helix 12 of the vitamin D receptor in SMRT corepressor interaction.Biochem Biophys Res Commun,2009,379:780-784.

共引文献44

同被引文献23

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部